Although vascular plugs for the closure of patent ductus arteriosus (PDA) have been validated in dogs, studies are lacking on its use as a first-choice device with a transjugular approach. The present case series describes the transvenous right jugular embolization of PDA using an Amplatzer Vascular Plug II in seven dogs of different ages, breeds, and body weights. Complete closure of the PDA was demonstrated in all cases. All dogs showed significant hemodynamic reduction of pulmonary overcirculation and left heart size after the procedure and at following echocardiographic check-ups. Transjugular PDA occlusion using an Amplatzer Vascular Plug II can thus be considered as a safe alternative to the arterial or venous femoral approach using an Amplatzer canine ductal occluder (ACDO), particularly in puppies with small femoral vessels.

Pulmonary valve stenosis (PS) in dogs is usually suspected due to the presence of a heart murmur and clinical signs. Echocardiography is needed to confirm the diagnosis and define the severity of PS. This retrospective study evaluated the utility of clinical and electrocardiographic (ECG) findings in the prediction of PS severity. Data regarding heart murmur and ECG analysis were gathered. Ninety-seven dogs with PS were included. A murmur grade ≥IV/VI was predictive of severe PS (area under curve (AUC) = 0.71; sensitivity (Se) = 95%; specificity (Sp) = 33%; p = 0.003). In lead II, P wave amplitude >0.35 mV (AUC = 0.67; Se = 31%; Sp = 100%; p = 0.038), Q wave < 0.15 mV (AUC = 0.70; Se = 70%; Sp = 59%; p = 0.0015), R wave < 0.87 mV (AUC = 0.66; Se = 67%; Sp = 69%; p = 0.006), and S wave > 0.37 mV (AUC = 0.80; Se = 72%; Sp = 85%; p < 0.0001) were predictive of severe PS. The extent of right deviation of the mean electrical axis of the QRS complex was correlated with the pulmonary pressure gradient (r = 0.648; p < 0.0001). In conclusion, a systolic murmur with intensity ≥IV/VI, a P wave amplitude >0.35 mV, low amplitude of Q and R waves, deep S waves in lead II, and right axis deviation of the QRS complex in a young dog are predictive of severe PS.

Percutaneous balloon dilation was performed in a Rhodesian Ridgeback and in an American Staffordshire Terrier affected by cor triatriatum dexter (CTD). Both cases had ascites without jugular venous distension or pleural effusion. In both dogs the CTD presented a perforated membrane but with different morphology: in one case the coronary sinus entered the caudal chamber of the CTD together with the caudal vena cava. In the other case, the coronary sinus communicated with the cranial chamber of the CTD together with the cranial vena cava. Percutaneous balloon dilation of the CTD was successfully performed, and both dogs had uneventful surgery recoveries. At two years of follow-up, the dogs were free from clinical signs and cardiac medication.

Myxomatous mitral valve disease (MMVD) is a common cardiac disorder in older small- to medium-sized dogs. Diagnosis and staging are primarily based on echocardiography; however, circulating cardiac biomarkers have gained increasing interest because they are rapid and easily measurable. In this context, the investigators’ aim was to study the clinical value of galectin-3 (Gal-3) and trimethylamine N-oxide (TMAO), in dogs affected by MMVD, in comparison to cardiac troponin I (cTnI), a well-established biomarker of myocardial injury, and echocardiography. Twenty-two dogs were classified as healthy controls or affected by MMVD and staged according to American College of Veterinary Internal Medicine (ACVIM) guidelines. Serum concentrations of Gal-3, TMAO, and cTnI were measured and compared among groups. No significant differences in serum Gal-3 concentration were detected among groups (p = 0.955). In contrast, TMAO levels were significantly higher in both asymptomatic and symptomatic dogs compared with healthy controls (both p < 0.001). Serum cTnI showed limited sensitivity, with increased values observed only in some symptomatic dogs. Despite study limitations, including small sample size and demographic differences among groups, these preliminary findings suggest that TMAO could be a potential biomarker associated with MMVD development and progression; however, further studies are needed to confirm this association.